A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma
2019
Background
We conducted a phase III trial of personalized peptide vaccination (PPV) for human leukocyte antigen (HLA)-A24+ recurrent glioblastoma to develop a new treatment modality.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
18
References
21
Citations
NaN
KQI